Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.
The United States Patent and Trademark Office has issued on March 15th the US Patent number 9283206 covering the use of trimethylangelicin (TMA) as CFTR Corrector in Bronchial Epithelial Cells.
Rare Partners Charity Partner at SuisseGas Milano Marathon 2016.
Run4Usher, #runandimagetofly with us for Usher Syndrome.
The European Commission grants Orphan Drug Designation to Sirolimus (Rapamycin) for the treatment of beta thalassaemia intermedia and major